Literature DB >> 17327399

Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD.

Kelli P A MacDonald1, Rachel D Kuns, Vanessa Rowe, Edward S Morris, Tatjana Banovic, Helen Bofinger, Brendan O'Sullivan, Kate A Markey, Alistair L Don, Ranjeny Thomas, Geoffrey R Hill.   

Abstract

Antigen-presenting cells (APCs) are critical for the initiation of graft-versus-host disease (GVHD), although the responsible APC subset and molecular mechanisms remain unclear. Because dendritic cells (DCs) are the most potent APCs and the NF-kB/Rel family member RelB is associated with DC maturation and potent APC function, we examined their role in GVHD. Within 4 hours of total body irradiation, RelB nuclear translocation was increased and restricted to CD11c(hi) DCs within the host APC compartment. Furthermore, the transient depletion of CD11c(hi) donor DCs that reconstitute in the second week after transplantation resulted in a transient decrease in GVHD severity. By using RelB(-/-) bone marrow chimeras as transplant recipients or RelB(-/-) donor bone marrow, we demonstrate that the induction and maintenance of GVHD is critically dependent on this transcription factor within both host and donor APCs. Critically, RelB within APCs was required for the expansion of donor helper T cell type 1 (Th1) effectors and subsequent alloreactivity, but not the peripheral expansion or function of donor FoxP3(+) regulatory T cells. These data suggest that the targeted inhibition of nuclear RelB translocation within APCs represents an attractive therapeutic strategy to dissociate effector and regulatory T-cell function in settings of Th1-mediated tissue injury.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327399     DOI: 10.1182/blood-2007-01-067249

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 2.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

3.  IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.

Authors:  Ying Lu; Cynthia R Giver; Akshay Sharma; Jian Ming Li; Katarzyna A Darlak; Lauren M Owens; John D Roback; Jacques Galipeau; Edmund K Waller
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

4.  Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.

Authors:  Motoko Koyama; Rachel D Kuns; Stuart D Olver; Neil C Raffelt; Yana A Wilson; Alistair L J Don; Katie E Lineburg; Melody Cheong; Renee J Robb; Kate A Markey; Antiopi Varelias; Bernard Malissen; Günter J Hämmerling; Andrew D Clouston; Christian R Engwerda; Purnima Bhat; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Nat Med       Date:  2011-11-29       Impact factor: 53.440

5.  NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice.

Authors:  Susan E Murray; Fanny Polesso; Alexander M Rowe; Soumen Basak; Yoshinobu Koguchi; Katelynne Gardner Toren; Alexander Hoffmann; David C Parker
Journal:  J Clin Invest       Date:  2011-12       Impact factor: 14.808

6.  Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10.

Authors:  Kelli P A MacDonald; Laetitia Le Texier; Ping Zhang; Helen Morris; Rachel D Kuns; Katie E Lineburg; Lucie Leveque; Alistair L Don; Kate A Markey; Slavica Vuckovic; Frederik O Bagger; Glen M Boyle; Bruce R Blazar; Geoffrey R Hill
Journal:  J Immunol       Date:  2014-02-28       Impact factor: 5.422

Review 7.  Next generation treatment of acute graft-versus-host disease.

Authors:  J Magenau; P Reddy
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

8.  Efficacy of azithromycin in preventing lethal graft-versus-host disease.

Authors:  S Iwamoto; E Azuma; T Kumamoto; M Hirayama; T Yoshida; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

9.  Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models.

Authors:  Mareike Florek; Emanuela I Sega; Dennis B Leveson-Gower; Jeanette Baker; Antonia M S Müller; Dominik Schneidawind; Everett Meyer; Robert S Negrin
Journal:  Blood       Date:  2014-07-16       Impact factor: 22.113

Review 10.  Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation?

Authors:  Vinodh Pillai; Nitin J Karandikar
Journal:  Immunol Lett       Date:  2007-09-29       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.